ATC code C01

ATC codes

C Cardiovascular system

C01 Cardiac therapy

C02 Antihypertensives

C03 Diuretics

C04 Peripheral vasodilators

C05 Vasoprotectives

C07 Beta blocking agents

C08 Calcium channel blockers

C09 Agents acting on the renin-angiotensin system

C10 Lipid modifying agents

ATC code C01 Cardiac therapy is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup C01 is part of the anatomical group C Cardiovascular system.^[1]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: QC01...^[2] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

C01A Cardiac glycosides

C01AA Digitalis glycosides

C01AA01 Acetyldigitoxin

C01AA02 Acetyldigoxin

C01AA03 Digitalis leaves

C01AA04 Digitoxin

C01AA05 Digoxin

C01AA06 Lanatoside C

C01AA07 Deslanoside

C01AA08 Metildigoxin

C01AA09 Gitoformate

C01AA52 Acetyldigoxin, combinations

C01AB Scilla glycosides

C01AB01 Proscillaridin

C01AB51 Proscillaridin, combinations

C01AC Strophanthus glycosides

C01AC01 G-strophanthin

C01AC03 Cymarin

C01AX Other cardiac glycosides

C01AX02 Peruvoside

C01B Antiarrhythmics, class I and III

C01BA Antiarrhythmics, class Ia

C01BA01 Quinidine

C01BA02 Procainamide

C01BA03 Disopyramide

C01BA04 Sparteine

C01BA05 Ajmaline

C01BA08 Prajmaline

C01BA12 Lorajmine

C01BA51 Quinidine, combinations excluding psycholeptics

C01BA71 Quinidine, combinations with psycholeptics

C01C Cardiac stimulants excluding cardiac glycosides

C01CA Adrenergic and dopaminergic agents

C01CA01 Etilefrine

C01CA02 Isoprenaline

C01CA03 Norepinephrine

C01CA04 Dopamine

C01CA05 Norfenefrine

C01CA06 Phenylephrine

C01CA07 Dobutamine

C01CA08 Oxedrine

C01CA09 Metaraminol

C01CA10 Methoxamine

C01CA11 Mephentermine

C01CA12 Dimetofrine

C01CA13 Prenalterol

C01CA14 Dopexamine

C01CA15 Gepefrine

C01CA16 Ibopamine

C01CA17 Midodrine

C01CA18 Octopamine

C01CA19 Fenoldopam

C01CA21 Cafedrine

C01CA22 Arbutamine

C01CA23 Theodrenaline

C01CA24 Epinephrine

C01CA25 Amezinium metilsulfate

C01CA26 Ephedrine

C01CA27 Droxidopa

C01CA30 Combinations

C01CA51 Etilefrine, combinations

C01CE Phosphodiesterase inhibitors

C01CE01 Amrinone

C01CE02 Milrinone

C01CE03 Enoximone

C01CE04 Bucladesine

QC01CE90 Pimobendane

C01CX Other cardiac stimulants

C01CX06 Angiotensinamide

C01CX07 Xamoterol

C01CX08 Levosimendan

C01D Vasodilators used in cardiac diseases

C01DA Organic nitrates

C01DA02 Glyceryl trinitrate

C01DA04 Methylpropylpropanediol dinitrate

C01DA05 Pentaerithrityl tetranitrate

C01DA07 Propatylnitrate

C01DA08 Isosorbide dinitrate

C01DA09 Trolnitrate

C01DA13 Eritrityl tetranitrate

C01DA14 Isosorbide mononitrate

C01DA20 Organic nitrates in combination

C01DA38 Tenitramine

C01DA52 Glyceryl trinitrate, combinations

C01DA54 Methylpropylpropanediol dinitrate, combinations

C01DA55 Pentaerithrityl tetranitrate, combinations

C01DA57 Propatylnitrate, combinations

C01DA58 Isosorbide dinitrate, combinations

C01DA59 Trolnitrate, combinations

C01DA63 Eritrityl tetranitrate, combinations

C01DA70 Organic nitrates in combination with psycholeptics

C01DB Quinolone vasodilators

C01DB01 Flosequinan

C01DX Other vasodilators used in cardiac diseases

C01DX01 Itramin tosilate

C01DX02 Prenylamine

C01DX03 Oxyfedrine

C01DX04 Benziodarone

C01DX05 Carbocromen

C01DX06 Hexobendine

C01DX07 Etafenone

C01DX08 Heptaminol

C01DX09 Imolamine

C01DX10 Dilazep

C01DX11 Trapidil

C01DX12 Molsidomine

C01DX13 Efloxate

C01DX14 Cinepazet

C01DX15 Cloridarol

C01DX16 Nicorandil

C01DX18 Linsidomine

C01DX19 Nesiritide

C01DX21 Serelaxin

C01DX51 Itramin tosilate, combinations

C01DX52 Prenylamine, combinations

C01DX53 Oxyfedrine, combinations

C01DX54 Benziodarone, combinations

C01E Other cardiac preparations

C01EA Prostaglandins

C01EA01 Alprostadil

C01EB Other cardiac preparations

C01EB02 Camphor

C01EB03 Indometacin

C01EB04 Crataegus glycosides

C01EB05 Creatinolfosfate

C01EB06 Fosfocreatine

C01EB07 Fructose 1,6-diphosphate

C01EB09 Ubidecarenone

C01EB10 Adenosine

C01EB11 Tiracizine

C01EB13 Acadesine

C01EB15 Trimetazidine

C01EB16 Ibuprofen

C01EB17 Ivabradine

C01EB18 Ranolazine

C01EB21 Regadenoson

C01EB22 Meldonium

References

↑ "ATC/DDD Index 2016: code C01". WHO Collaborating Centre for Drug Statistics Methodology.
↑ "ATCvet Index 2016: code QC01". WHO Collaborating Centre for Drug Statistics Methodology.

Cardiac glycosides (C01A)

Bufadienolides

Bufo	Arenobufagin Bufotalin Cinobufagin Marinobufagin

Scilla	Proscillaridin Scilliroside

Cardenolides

Digitalis	Acetyldigitoxin Acetyldigoxin Digitoxin^# Digoxin^# Lanatoside C Deslanoside Metildigoxin Gitoformate

Kalanchoe	Daigremontianin

Strophanthus	Ouabain (g-Strophanthin) k-Strophanthin Cymarin

Thevetia	Peruvoside

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Antiarrhythmic agents (C01B)

Channel blockers

class I
(Na⁺ channel blockers)

class Ia (Phase 0→ and Phase 3→)	Ajmaline Disopyramide Lorajmine Prajmaline Procainamide^# Quinidine^# Sparteine

class Ib (Phase 3←)	IV (Lidocaine^#) enteral (Aprindine Mexiletine Tocainide)

class Ic (Phase 0→)	Encainide^‡ Ethacizine Flecainide Indecainide^‡ Lorcainide Moracizine^‡ Propafenone

class III
(Phase 3→, K⁺ channel blockers)

class IV
(Phase 4→, Ca²⁺ channel blockers)

Diltiazem
Verapamil^#

Receptor agonists
and antagonists

class II (Phase 4→, β blockers)	Nadolol Pindolol Propranolol cardioselective (Acebutolol Atenolol Esmolol Metoprolol)

A₁ agonist	Adenosine Benzodiazepines Barbiturates

M₂	muscarinic antagonist: Atropine Disopyramide Quinidine muscarinic agonist: Digoxin

α receptors	Amiodarone Bretylium Quinidine Verapamil

Ion transporters

Na⁺/ K⁺-ATPase	Digoxin

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Cardiac stimulants excluding cardiac glycosides (C01C)

Adrenergic and
dopaminergic agents

Adrenergic agonists

α	Metaraminol Phenylephrine Methoxamine Norfenefrine Oxedrine Midodrine Mephentermine

β	Dobutamine Arbutamine Isoprenaline Prenalterol

mixed	Amezinium metilsulfate Droxidopa Epinephrine # Norepinephrine Etilefrine

Dopamine agonists

Fenoldopam

Both

Unknown/ungrouped

Phosphodiesterase inhibitors (PDE3I)

Other cardiac stimulants

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Vasodilators used in cardiac diseases (C01D)

Nitrovasodilators	Nitroglycerin # Isosorbide dinitrate # Isosorbide mononitrate Linsidomine Molsidomine Nicorandil Pentaerythritol tetranitrate Propatylnitrate Tenitramine Trolnitrate

Quinolone vasodilators	Flosequinan^‡

Others	Benziodarone Carbocromen Cinepazet Cloridarol Dilazep Efloxate Etafenone Gapicomine Heptaminol Hexobendine Imolamine Itramin tosilate Levosimendan Nesiritide Nicorandil Oxyfedrine Pimobendan Prenylamine Serelaxin Trapidil

^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

This article is issued from Wikipedia - version of the Monday, January 04, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.